Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065; email:
Annu Rev Med. 2017 Jan 14;68:255-269. doi: 10.1146/annurev-med-042915-103905. Epub 2016 Sep 23.
Psoriasis vulgaris, affecting the skin, is one of the most common organ-specific autoimmune diseases in humans. Until recently, psoriasis was treated by agents or approaches discovered largely through serendipity. Many of the available drugs were inherently quite toxic when used as continuous treatment for many years in this chronic disease. However, an increasing understanding of disease-specific immune pathways has spurred development of pathway-targeted therapeutics during the past decade. Psoriasis is now the most effectively treated human autoimmune disease, with high-level clinical improvements possible in ∼90% of patients using a new generation of drugs that selectively target the IL-23/Type 17 T cell axis. Thus, psoriasis is a model for the success of a translational-medicine approach based on cellular and molecular dissection of disease pathogenesis in humans.
寻常型银屑病，累及皮肤，是人类最常见的器官特异性自身免疫性疾病之一。直到最近，银屑病的治疗药物或方法主要还是通过偶然发现的。在这种慢性疾病中，许多现有的药物在多年的连续治疗中都具有固有的毒性。然而，对疾病特异性免疫途径的认识不断加深，促使过去十年中开发了针对途径的治疗药物。目前，银屑病是治疗效果最显著的人类自身免疫性疾病，约 90%的患者使用新一代药物进行治疗后可获得高水平的临床改善，这些药物选择性地针对 IL-23/Type 17 T 细胞轴。因此，银屑病是基于人类疾病发病机制的细胞和分子解析的转化医学方法成功的典范。
